News
CMXHF
119.00
NaN%
--
CSL Limited Announces Cessation of Securities
TipRanks · 6h ago
CSL Limited Updates on Share Buy-Back Progress
TipRanks · 9h ago
Morgan Stanley Sticks to Their Buy Rating for CSL (CMXHF)
TipRanks · 1d ago
BUZZ-Morningstar sees Australia's CSL as 'cheap', optimistic for margin rebound
Reuters · 1d ago
CSL Limited Appoints Gordon Naylor as Director
TipRanks · 2d ago
CSL Limited Announces Issuance of Unquoted Equity Securities
TipRanks · 2d ago
CSL Limited Updates on Share Buy-Back Program
TipRanks · 11/26 22:08
CSL Limited Updates on Ongoing Share Buy-Back
TipRanks · 11/25 22:29
Jarden Sticks to Its Buy Rating for CSL (CMXHF)
TipRanks · 11/25 00:36
CSL Limited Director Increases Stake with Significant ADR Purchase
TipRanks · 11/23 21:57
CSL Limited Updates on Market Buy-Back Program
TipRanks · 11/23 21:57
Washington state resident dies from bird flu strain never before detected in humans
Seeking Alpha · 11/22 13:33
CSL Limited Updates on Ongoing Share Buy-Back Program
TipRanks · 11/20 21:43
CSL Limited Updates on Market Buy-Back Program
TipRanks · 11/19 22:17
Australian biotech CSL announces $1.5B investment in the U.S.
Seeking Alpha · 11/18 15:59
BRIEF-CSL To Invest $1.5 Bln In U.S. To Manufacture Plasma-Derived Therapies
Reuters · 11/18 14:48
CSL Limited Announces $1.5 Billion U.S. Expansion for Plasma Therapy Manufacturing
Reuters · 11/18 12:19
Analysts Conflicted on These Healthcare Names: CSL (OtherCMXHF) and Ramsay Health Care (OtherRMSYF)
TipRanks · 11/16 22:40
CSL Limited Updates on Ongoing Share Buy-Back Program
TipRanks · 11/16 22:28
More
Webull provides a variety of real-time CMXHF stock news. You can receive the latest news about CSL through multiple platforms. This information may help you make smarter investment decisions.
About CMXHF
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.